Sphingosine
CAS 123-78-4
Sphingosine (CAS 123-78-4) is a pharmaceutical compound with 5 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 22395.629787234044 nM | 37 | - |
| - | IC50 | 16203.782608695652 nM | 23 | - |
| - | MIC | 16.8 ug.mL-1 | 5 | - |
| - | EC50 | 4059.3333333333335 nM | 3 | - |
| - | MIC | 100000 nM | 1 | - |
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| TRPM3 TRPM3 |
Agonist | 4.900000095367432 pEC50 | 15550678 |
| TRPM7 Trpm7 |
Inhibition | 6.230000019073486 pIC50 | 23145923 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Sphingosine used for in pharmaceutical contexts?
Sphingosine (CAS 123-78-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Sphingosine?
No adverse-event association or SIDER side-effect rows are rendered for Sphingosine in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Sphingosine also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Sphingosine with EU status "permitted".
What clinical phase is Sphingosine in?
No phase 1-4 clinical development badge is rendered for Sphingosine because the matched compound identifier rows do not contain a max-phase value.